Autor: |
Roger Trinh, Akshanth R. Polepally, Natarajan Ravendhran, Leslie Bank, Paul J. Pockros, Robert Reindollar, Fred Poordad, Marisol Martinez, Michael S. Epstein, David E. Bernstein, David R. Nelson, Shahriar Sedghi, Michael R. Lucey, Preethi Krishnan, Kristina Unnebrink |
Rok vydání: |
2019 |
Předmět: |
|
Zdroj: |
Journal of Viral Hepatitis |
ISSN: |
1365-2893 1352-0504 |
DOI: |
10.1111/jvh.13109 |
Popis: |
Patients infected with hepatitis C virus (HCV) treated with interferon‐free direct‐acting antivirals may still require ribavirin. However, ribavirin is associated with adverse events that can limit its use. This open‐label, multicentre, Phase 3 study evaluated the safety and efficacy of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) with low‐dose ribavirin for 12 weeks in genotype 1a‐infected patients without cirrhosis. The primary efficacy endpoint was sustained virologic response at post‐treatment Week 12 (SVR12). The primary safety endpoint was haemoglobin |
Databáze: |
OpenAIRE |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|